Labcorp announced it has received de novo marketing authorization from FDA for PGDx elio plasma focus Dx—the industry’s first and only kitted, pan-solid tumor liquid biopsy test.
DNA/RNA material contained in circulating extracellular vesicles secreted into the bloodstream by tumor cells captures cancer genomics and transcriptomic evolution in patients with metastatic prostate cancer, according to a new study.
Helio Genomics, an AI-driven healthcare company specializing in diagnostics technology and test development for cancer detection, has released results from its latest clinical trial demonstrating the superior performance of their HelioLiver Dx test compared to ultrasound.
FDA’s Medical Devices Advisory Committee has strongly recommended FDA approval of Guardant Health’s Shield blood test for colorectal cancer screening in adults age 45 and older who are at average risk for the disease.
Data published in The Journal for ImmunoTherapy of Cancer show ClearNote Health’s epigenomic platform may provide a novel tissue-free, liquid biopsy-based approach for prediction and monitoring of immunotherapy response for non-small cell lung cancer patients.
Multi-cancer detection tests evoke conflicting reactions—the excitement at their promise is quickly dampened by concerns over the uncertainty of their clinical benefit, very low sensitivity for detecting stage 1 cancers, and the risks that come from subsequent workups.
Researchers from University of Pittsburgh and Washington University School of Medicine in St. Louis found that liquid from surgical drains, which is usually tossed in the trash, could inform more precise treatments for patients with head and neck cancer caused by human papillomavirus.
Liquid biopsy tests may someday upend screening as we know it. The promise of broad screening employing “multi-cancer detection” has spawned consortia and inspired enthusiastic opinion articles.
Results from a phase II study, led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy, BC Cancer, and the Canadian Cancer trials Group, suggest that circulating tumor DNA analyses could be used as an early marker of immunotherapy response in advanced non-small cell lung cancer patients and may help guide therapy.
A study on human tissue and plasma led by researchers at USC Norris Comprehensive Cancer Center shows that their newly developed blood test, OvaPrint, may distinguish between cancerous and benign pelvic masses with up to 91% accuracy, surpassing other commercially available tests.
